Please enable Javascript
Matthew Galsky, MD
Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai
Articles by Matthew Galsky, MD
Pioneering Advances in Bladder Cancer: New Drug Classes, Biomarkers, and Treatment Models
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
March 13, 2025
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
View More
Utility of ctDNA, Overcoming Barriers to Multidisciplinary Care in Community, Academic Settings
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
March 13, 2025
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
View More
Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
March 13, 2025
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
View More
Post-EV/Pembro Progression: How Real-World Data is Shaping 2L Treatment Decisions
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
March 13, 2025
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
View More
Balancing EV/Pembro and Gem/Cis-Nivo: Selecting the Right 1L Therapy for Node-Only Disease
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
March 13, 2025
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
View More
Redefining Urothelial Cancer Care: EV-Pembro, De-Escalation, and Future Strategies
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
March 13, 2025
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
View More
NIAGARA: Impact of pCR on Long-Term Outcomes
Matthew Galsky, MD
Muscle Invasive Urothelial Carcinoma
|
February 14, 2025
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
View More
CheckMate 274: Additional Efficacy Outcomes in Patients With MIBC
Matthew Galsky, MD
Muscle Invasive Urothelial Carcinoma
|
February 20, 2025
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
View More
Disitamab Vedotin Plus Pembrolizumab in aUC: HER2 Status, Safety and Efficacy Data
Matthew Galsky, MD
Advanced Urothelial Carcinoma
|
September 18, 2024
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
View More
Disitamab Vedotin With Pembrolizumab Versus Chemotherapy for la/mUC Expressing HER2
Matthew Galsky, MD
Advanced Urothelial Carcinoma
|
June 6, 2024
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
View More
CheckMate 901: Characterizing Complete Responders, Patients With Lymph Node-Only mUC
Matthew Galsky, MD
Advanced Urothelial Carcinoma
|
June 6, 2024
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
View More
CheckMate 274: OS Outcomes for Patients With MIBC
Matthew Galsky, MD
Muscle Invasive Urothelial Carcinoma
|
May 20, 2024
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
View More
Panel Shares Predictions for What’s to Come in Advanced Urothelial Carcinoma
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
View More
Panelists Share Best Practices, Strategies for Community Oncologists Managing Patients on EV/Pembro
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
View More
Bladder Panel Talks Treatment Sequencing and Decisions in Different Patient Cases
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
View More
Combination Antibody-Drug Conjugate Strategy and the Future of Bladder Treatment
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
View More
Reactions to Phase 3 THOR Study: Primary End Point Not Met
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares lessons learned from the phase THOR study.
View More
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discusses the CheckMate 901 study results.
View More
EV-302 Results and How They Compare to the JAVELIN Paradigm
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
View More
Bladder Panel Reacts to EV-302 Data Presented at ESMO 2023
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
View More
Load More